Table I.
Characteristics of the study group (N=151)
| Median [Range] | n (%) | |
|---|---|---|
| Age (years). Mean (95%CI) | 69 (67–70) [50–88] | |
|
| ||
| Female | 44 (29.1) | |
|
| ||
| Hgb (g/dl). Mean (95%CI) | 10.9 (10.6–11.2) | |
|
| ||
| Platelets (×109/L) | 85.5 [11.0–795.0] | |
|
| ||
| WBC (×109/L) | 16.0 [2.7–211.8] | |
|
| ||
| ANC (×109/L) | 8.4 [0.2–108.0] | |
|
| ||
| Monocytes (×109/L) | 2.9 [0.4–48.7] | |
|
| ||
| Lymphocytes (×109/L) | 2.3 [0.2–18.8] | |
|
| ||
| BM Blast (%) | 7 [0–18] | |
|
| ||
| PB Blast (%) | 0 [0–16] | |
|
| ||
| WHO CMML classification | ||
| CMML-0 | 40 (26.5) | |
| CMML-1 | 58 (38.7) | |
| CMML-2 | 52 (34.7) | |
|
| ||
| FAB classification | ||
| Dysplastic subtype | 65 (43.0) | |
| Proliferative subtype | 86 (57.0) | |
|
| ||
| AML transformation | 49 (32.5) | |
|
| ||
| Modified Spanish cytogenetic risk | ||
| Low | 105 (71.4) | |
| Intermediate | 27 (18.4) | |
| High | 15 (10.2) | |
|
| ||
| Therapy related | 45 (29.8) | |
|
| ||
| CPSS | ||
| Low | 17 (14.7) | |
| Intermediate-1 | 45 (38.8) | |
| Intermediate-2 | 42 (36.2) | |
| High | 12 (10.3) | |
|
| ||
| MDAPS | ||
| Low | 61 (40.9) | |
| Intermediate-1 | 47 (31.5) | |
| Intermediate-2 | 30 (20.1) | |
| High | 11 (7.4) | |
|
| ||
| MCPS | ||
| Low | 22 (17.6) | |
| Intermediate | 68 (54.4) | |
| High | 35 (28.0) | |
|
| ||
| IPSS | ||
| Low | 30 (20.3) | |
| Intermediate-1 | 67 (45.3) | |
| Intermediate-2 | 44 (29.7) | |
| High | 7 (4.7) | |
|
| ||
| Treatment | ||
| 5-Azacitidine | 35 (23.2) | |
| Decitabine | 73 (48.3) | |
| Azacitidine-based combinations | 30 (19.9) | |
| Decitabine-based combinations | 13 (8.6) | |
CMML: chronic myelomonocytic leukemia; Hgb: Hemoglobin; WBC: white blood cells; ANC: absolute neutrophil count; BM: bone marrow; PB: peripheral blood; AML: acute myeloblastic leukemia; CPSS: CMML-specific prognostic scoring system; MDAPS: MD Anderson Cancer Center Prognostic Score System; MCPS: Mayo Clinic Prognostic Score; IPSS: international prognostic score system.